Immunotherapy plus chemo and radiation: new hope for lung cancer?

NCT ID NCT07138755

Recruiting now Disease control Sponsor: The Third Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and a tailored radiation plan can help people with stage III non-small cell lung cancer. The study will enroll 35 adults who cannot have surgery. Researchers will track how long the cancer stays under control and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab (an immunotherapy drug) combined with platinum-based chemotherapy (cisplatin or carboplatin plus paclitaxel or pemetrexed) and adaptive radiotherapy
What this could lead to: If successful, this combination could improve control of stage III lung cancer and delay disease progression, offering a new treatment option.
What could go wrong: This is a small, early-phase trial with only 35 participants, so results may not apply broadly. Side effects from the drug combination and radiation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADAPTIVE RADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADAPTIVE RADIOTHERAPY NSCLC SINTILIMAB

Contacts and locations

Locations

Xiangya 3rd Hospital, Central South University
RECRUITING

Changsha, Hunan, 410013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.